

1 **Enhanced Nanoparticle Uptake into Virus Infected Cells: Could Nanoparticles be useful**
2 **in Antiviral Therapy?**

3 Yasmin Abo-zeid^{1,4}, Richard A. Urbanowicz^{2,3}, Brian J. Thomson ², William L. Irving ^{2,3},
4 Alexander W. Tarr^{2,3}, Martin C. Garnett¹

5

6 ¹School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK.

7 ² NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust
8 and the University of Nottingham, Nottingham, UK

9 ³ School of Life Sciences, Faculty of Medicine & Health Sciences, Queens Medical Centre,
10 University of Nottingham, Nottingham, NG7 2UH, UK.

11 ⁴School of Pharmacy, Helwan University, Cairo, Egypt

12

13 **Corresponding Author:**

14 Yasmin Abo-zeid^{1,4}

15 **E-mail :** Yasmin.Abozeid@nottingham.ac.uk

16 **Mobile :** [+44073066025](tel:+44073066025)

17

18 **Co-Authors:**

19 Richard A. Urbanowicz ^{2,3}

20 Email:Richard.Urbanowicz@nottingham.ac.uk

21

22 Brian J. Thomson²

23 Email: Brian.thomson@nottingham.ac.uk

24

25

26 William L. Irving^{2,3}

27 **E-mail:** Will.Irving@nottingham.ac.uk

28

29 Alexander W. Tarr^{2,3}

30 Email: Alex.Tarr@nottingham.ac.uk

31

32 Martin C. Garnett¹

33 Email : martin.garnett@nottingham.ac.uk

34

35 **Abstract:**

36 Virus infections cause diseases of different severity ranged from mild infection e.g. common
37 cold into life threatening diseases e.g. Human Immunodeficiency virus (HIV), Hepatitis B. Virus
38 infections represent 44% of newly emerging infections. Although there are many efficient
39 antiviral agents, they still have drawbacks due to accumulation at off target organs and
40 developing of virus resistance due to virus mutation. Therefore, developing a delivery system
41 that can selectively target drug into affected organs and avoid off target accumulation would
42 be a highly advantageous strategy to improve antiviral therapy. Nanoparticles (NP) can be
43 effectively targeted to the liver, and therefore it could be used for improving therapy of hepatic
44 virus infections including hepatitis B virus and hepatitis C virus (HCV). Many studies were
45 performed to encapsulate antiviral agents into nano-delivery system to improve their
46 pharmacokinetics parameters to have a better therapeutic efficacy with lower side effects.
47 However, the effect of virus infection on the uptake of NP has not yet been studied in detail.
48 The latter is a crucial area as modulation of endocytic uptake of nanoparticles could impact on
49 reduce potential therapeutic usefulness of antiviral agents loaded into nano-delivery system. In
50 this study, a fluorescently-labelled polymeric nanoparticle was prepared and used to track NP
51 uptake into Huh7.5, human hepatoma cells transfected with replicating HCV genomes,
52 compared with non-transfected cells as a model representing hepatocyte uptake. Confocal
53 microscopy and flow cytometry of virus transfected Huh7.5 cells unexpectedly demonstrated
54 two-fold increase in uptake of NP compared to non-transfected cells. Therefore, virus
55 transfection enhanced NP uptake into Huh7.5 cells and NP could be considered as a promising
56 delivery system for targeted treatment of hepatitis viruses..

57

58 **Keywords:** HCV infection, Polymer nanoparticles; Poly(glycerol adipate); Huh7.5 cells

59 **Introduction:**

60 Emerging infectious diseases (EID) present a considerable threat to human life on earth.
61 Viruses are the largest and most genetically diverse biomass on earth (Suttle, 2005) and account
62 for 44% of EID (Taylor et al., 2001). Itaya virus, Iquitos virus, Ngari virus and Ilesha virus that
63 are new emerging viruses in South America and East Africa (Wiwanitkit and Wiwanitkit,
64 2015), chikungunya virus has spread worldwide (Rothan et al., 2016), and Zika virus is now a
65 major global health threat (Lazear and Diamond, 2016); (Paixão et al., 2016).

66 Emerging viruses therefore present a major public health and therapeutic challenge.
67 Fortunately, it is known that viruses belonging to the same family, share similar characteristics
68 (King et al., 2012). This allows many newly emerged viruses to be treated with established
69 Food and Drug Administration (FDA) approved antiviral agents (Tan et al., 2017); (Yeo et al.,
70 2015). Currently, there are around 90 active antiviral drugs approved for the effective treatment
71 of many types of virus infections (Clercq, 2016). However, their administration is accompanied
72 by side effects that can limit their potential use. E.g. ribavirin causes haemolytic anaemia
73 (Hutchison et al., 2002), while other agents, including zidovudine, zalcitabine, lamivudine, and
74 abacavir may give rise to peripheral neuropathy, leukopenia, pancreatitis, gout and life-
75 threatening hypersensitivity reactions (Montessori et al., 2004). Development of antiviral
76 resistance due to virus mutation is an additional problem (Lembo et al., 2018). Side effects are
77 commonly due to accumulation of antiviral drug into off-target organs and therefore, finding a
78 way that could selectively deliver antiviral agents into the target organ whilst avoiding, or
79 reducing off-target accumulation is highly desirable and could improve the specificity and
80 efficacy of antiviral therapy. Nano-delivery systems are known to modify the physicochemical
81 properties e.g solubility and pharmacokinetics parameters (absorption, distribution,
82 metabolism and elimination) of the encapsulated materials via controlled drug release. They
83 can also be tailored for passive (e.g. controlling particle size) or active (surface decoration with

84 ligands) targeting of the therapeutic agents. Consequently, using a nano-delivery system for
85 antiviral therapy could result in a lower dose of antiviral agents and a reduced side effect profile
86 (Lembo et al., 2018). Nowacek and colleagues (Nowacek et al., 2012) prepared nanocrystals
87 (a nano-sized delivery system composed of 100% drug with no carrier) of antiretroviral agents
88 (Indinavir, Ritonavir, Atazanavir, and Efavirenz) as a way to improve their antiviral potency
89 against HIV. In vitro study showed that nanocrystals improved cellular uptake into monocyte-
90 derived macrophage (phagocytic cells) and reduced cytotoxicity compared to the free parent
91 drug. All nanocrystals showed antiretroviral activity ranging from 20% to 100%, depending on
92 the formulation and drug type (Nowacek et al., 2012). Although many studies have been
93 concerned with improvement of antiviral potency and trying to reduce its side effects via
94 encapsulation into nano-delivery system, the effect of virus infection on the uptake of NP into
95 host cells has not been studied in detail. A down-regulation of endocytosis by virus would
96 make NP delivery of the appropriate antiviral agent(s) less effective, whereas upregulation of
97 endocytosis in infected cells could facilitate targeted uptake of drug into infected cells and
98 further reduce side effects.

99 In order to address this important question, we used an established in vitro model of hepatitis
100 C virus (HCV) replication to interrogate the capacity of virus infection to modulate uptake of
101 NP. Therefore, in the current study, a fluorescently labelled polymer NP, Rhodamine B
102 isothiocyanate (RBITC) labelled NP prepared with the bio-compatible polymer, poly(glycerol-
103 adipate) [PGA] have been used in combination with Huh7.5 cells (non-phagocytic cells)
104 transfected with hepatitis C virus (J6/JFH1 chimera) to track how virus infection could
105 modulate the endocytic uptake of NP. Huh7.5 cells and the J6/JFH1 chimera have been used
106 in the current study because it was reported that Huh7.5 cells are highly permissive to HCV
107 infection (Lanford et al., 2003); (Sumpter et al., 2005) and the J6/JFH1 chimera (HCV RNA)

108 is considered as the most efficient replicating chimera in Huh7.5 cells (Lindenbach et al.,
109 2005).

110 **2. Materials and Methods:**

111 **2.1. Materials:**

112 All materials were purchased from Sigma-Aldrich and VWR and used as supplied except for
113 divinyladipate purchased from Tokyo Chemical Industry UK Ltd. Huh7.5, hepatocellular
114 carcinoma cells were supplied by Apath LLC. Phenol red free - Dulbecco's Modified Eagle
115 Medium (DMEM), foetal bovine serum (FBS), non-essential amino acids (NEAA), penicillin,
116 streptomycin, C7-50, mouse anti-HCV core protein antibody (primary antibody) and Alexa-
117 488, anti-mouse IgG antibody (secondary antibody) were supplied by Thermo Fisher.

118 **2.2. Methods:**

119 **2.2.1. Synthesis and characterisation of Poly(Glycerol adipate):**

120 PGA is a functionalized linear polyester. It was synthesized and characterised as previously
121 reported (Kallinteri et al., 2005); (Taresco et al., 2016). In brief, PGA was Enzymatically
122 synthesized where equal amounts (250 mmol) of glycerol and DVA were dissolved in dry
123 tetrahydrofuran (THF, 30 ml) in presence of a catalytic enzyme, Novozyme 435 (1.25 gm) and
124 the reaction was stirred (overhead stirrer, 200 rpm) at constant temp (50 °C) for 24h. This was
125 followed by enzyme filtration and evaporation of THF to obtain a yellowish jelly-like polymer.

126

127 **2.2.2. Preparation of fluorescently labelled nanoparticles:**

128 RBITC PGA NP were prepared by an interfacial deposition method as reported (Meng et al.,
129 2006) with the following modifications; RBITC (200 µl, 1 mg/ml, methanol) was added into
130 the aqueous phase (HEPES buffer, 10 mM, pH 7.4, 7ml). The polymer (20mg) dissolved in
131 acetone (2ml) was added dropwise into the aqueous phase while stirring. The organic solvent
132 was evaporated overnight. RBITC PGA NP were purified by loading the sample onto a
133 Sepharose CL-4B gel column (C2.5 X 40, Pharmacia, bed volume 91ml). The column was

134 eluted by water using a peristaltic pump at a flow rate of 1 ml/min and collected in fractions,
135 1.5ml/ tube. The peaks of dye labelled NP and free dye were detected using a Pharmacia
136 chromatographic UV detector (206nm filter). The purified NP dispersion was collected and
137 characterized using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK) at
138 25 °C ± 0.1. Particle size and zeta potential were measured in HEPES buffer (1 mM, pH 7.4)
139 The dye loading, and encapsulation percentages were determined by a direct method. A
140 weighed amount of freeze dried RBITC PGA NP was extracted by acetone: methanol (1:1) and
141 dye fluorescence was measured at λ_{Ex} , 545 nm and λ_{Em} , 575 nm. Then the concentration of dye
142 was determined from the calibration curve of known dye concentrations in acetone: methanol
143 (1:1) using a spectrophotofluorometer (Hitachi F-4500 Hitachi, place), with slit widths adjusted
144 to 5 nm.

145 **2.2.3. Stabilization of NP in physiological buffer:**

146 Either surfactants or human plasma were used to stabilize the RBITC PGA NP to physiological
147 salt concentrations, (1) polysorbate surfactants (Tween 80/Tween 20) were either added to give
148 a final concentrations 0.01% and 0.1% v/v to the pre-prepared NP (100 μ l, 100 μ g), or during
149 NP preparation (*in situ* addition). (2) Alternatively, freshly isolated human plasma (100 μ l)
150 was incubated with NP (100 μ l, 100 μ g) for 5 minutes or 24 h before addition of phosphate
151 buffered saline (PBS).

152 To investigate how PBS affects NP stability, RBITC PGA NP (100 μ l, 100 μ g) were diluted
153 with PBS followed by particle size measurement in PBS. The final volume for all the previous
154 samples was adjusted to 1 ml using PBS. For particle stability measurement, NP (100 μ l) were
155 diluted with HEPES buffer (1 mM, pH 7.4) to 1 ml and used as a control for NP size. Particle
156 size measurements were performed using the Malvern Zetasizer Nano ZS.

157

158 **2.2.4. Investigation of NP uptake by HCV virus transfected/non-transfected Huh7.5 cells:**

159 Huh7.5 cells (8×10^6) were electroporated in cytomix buffer (400 μ l) [potassium chloride (120
160 mM), calcium chloride (0.15 mM), di-potassium phosphate/ Mono-potassium phosphate (10
161 mM, pH 7.6)] in the absence (non-transfected cells) or presence (transfected cells) of a 10 μ g
162 of J6/JFH1 HCV chimeric RNA at 220V/22ms. Cells were then incubated in phenol red free -
163 DMEM containing 10% FBS, penicillin (100 U/ml), streptomycin (100 μ g/ml), and 1% NEAA
164 for 24 hours at 37°C and 5% CO₂.

165 For confocal microscopy, 5×10^4 of the previously electroporated cells (either virus transfected
166 or non-transfected cells) were added to wells of a 24-well cluster (Nunclon; Nunc) containing
167 glass cover slips. Cells were incubated for another 24 hours with phenol red free - DMEM (1
168 ml) followed by washing with PBS (1ml X 3). Phenol red free - DMEM (0.8 ml) and NP
169 stabilised with FBS (100 μ g, 200 μ l) were added to these cells followed by incubation at 37°C
170 and 5% CO₂ for different time intervals. Cells were washed with PBS, fixed using
171 paraformaldehyde, and then permeabilized with 0.5% TritonX-100 (400 μ l) for 5 minutes.
172 Virus core protein staining was carried out by addition of mAb C7-50 (1 μ g/ml; Thermo Fisher)
173 in PBS containing 5% FBS and incubated at room temperature (RT) for 45 minutes, followed
174 by PBS wash (400 μ l X 3). Cells were then incubated with Alexa-488 anti-mouse IgG (2 μ g/ml)
175 in 5% FBS in PBS for 60 min at RT and washed three times with PBS. Cell nuclei were stained
176 by incubation of 5 μ M 4', 6-diamidino-2-phenylindole (DAPI) in PBS with cells for 2-3
177 minutes at RT followed by three washes with PBS. To investigate the efficiency of virus core
178 protein expression, a set of virus transfected /non-transfected Huh7.5 cells that were not treated
179 with NP were prepared and processed under similar conditions, and imaged by fluorescence
180 microscopy (Leica DMRB).

181

182 For flow cytometry quantitative studies, the previously electroporated cells (1×10^5 /well) either
183 transfected or non-transfected were loaded onto 6 wells plate and incubated for another 24h.
184 Cells were washed three times with PBS. Then, phenol red free - DMEM (3.2ml) and NP/FBS
185 mixture, (400 μ g, 800 μ l) were added into cells followed by incubation at 37 $^\circ$ C and 5% CO₂. A
186 set of control cells was incubated with free RBITC (5 ng, equivalent to the dye amount that
187 might leak from RBITC PGA NP). After incubation for periods up to 4h, cells were washed
188 three times with PBS. Cells were detached and fixed with a mixture of 4% paraformaldehyde
189 and trypsin/EDTA (1:1) and transferred to flow cytometry tubes. Virus transfected cells were
190 washed twice with 1% FBS in PBS (2 ml, then 1 ml) followed by centrifugation (300 g, 5 min)
191 to remove the washing solution. Then, cells were permeabilised with PBS containing 1% FBS
192 and 0.04% saponin (1 ml) before removal of saponin solution by centrifugation (300 g, 5 min).
193 Cells were stained for virus core protein by incubation with C7-50 (40 μ g/ml) for 45 minutes at
194 RT, washed with the saponin mixture again and incubated with anti-mouse IgG Alexa-488
195 (80 μ g/ml) for 1h at RT. Cells were washed again with the saponin mixture (1ml) and suspended
196 in 4% paraformaldehyde. The mean fluorescence intensity (MFI) was determined using a
197 Beckman Coulter Moflo XPD flow cytometer. Another set of virus transfected cells were
198 incubated with NP for 4h without staining for virus to assess the possibility that
199 permeabilization step using saponin may lead to NP release from cells. NP uptake into virus
200 non-transfected cells was determined similarly to transfected cells but without addition of C7-
201 50 and Alexa-488-secondary antibody. All samples were analysed in triplicate.

202

203 **2.2.5. Statistical analysis:** Statistical analysis (Two Way ANOVA) were carried out using
204 SPSS version 21 at 95% confidence interval.

205

206

207 **3. Results and Discussion:**

208 **3.1. Synthesis and characterization of PGA:** The identity of PGA polymer was confirmed
209 by ¹H-NMR (data not shown), and size exclusion chromatography analysis gave an estimated
210 Mn,SEC = 11.6 KDa and molecular weight dispersity Đ of 1.4 and molecular weight (Mw) = 16
211 KDa.

212 **3.2. Preparation and characterization of nanoparticles:**

213 RBITC PGA NP were prepared by a nanoprecipitation method. NP with a size around 110 nm
214 were produced (Table 1) and had a good encapsulation efficiency percentage. Although zeta
215 potential values indicated that particles should be stable in low ionic strength media, further
216 investigations were carried out to ensure the particles did not aggregate under relevant
217 physiological conditions in (see section 3.3).

Table 1: Physicochemical characterization of RBITC PGA NP:

Name	Particle Size (dnm ± SD) *[PdI]	Zeta Potential (mv ± SD)	**% Load % (w/w) ± SD	***Encapsulation Efficiency % ± SD
RBITC PGA NP	110 ± 30[0.01]	- 53.7 ± 13.34	0.54 ± 0.13	54 ± 13

218 *PdI = polydispersity index, **% Load = [(Encapsulated dye weight/ NP weight) * 100]

219 *** % Encapsulation = [(Encapsulated dye weight/ Initial dye weight) * 100].

220 RBITC PGA NP was used in the current study to track the virus effect on the NP uptake into
221 Huh7.5 cells for several reasons, (1) RBITC dye is more stable than fluorescein to quenching
222 by light and fluorescence is improved in the acidic pH of the lysosomal compartment (Garnett
223 and Baldwin, 1986). (2) RBITC labelled PGA NP retain their dye label for prolonged periods
224 and so reduce possible artefacts in uptake studies as was demonstrated earlier in our group
225 (Meng et al., 2006) (3) The initial RBITC released from NP in culture medium over 24h was
226 very low (4.5%) (Meng et al., 2006) (4) Polymer biocompatibility and biodegradability is
227 important to be considered for the future therapy of polymer based nano-delivery system. The

228 degradation by-products of PGA are adipic acid and glycerol which are safe compounds as
229 approved by FDA (Zhang et al., 2014) (5) The cytotoxicity of PGA has been determined earlier
230 in our group (Kallinteri et al., 2005), and it showed a very low cell toxicity against Human
231 Leukaemia cell line, HL60 cell and Human liver cell lines, HepG2 cells at the top dose of
232 polymer NP, 100 times more of polymer amount required for a therapeutic nano-delivery
233 system. Also, Navarro and his colleagues (Navarro et al., 2017) have used PGA elastomer and
234 it was demonstrated to be non-cytotoxic to embryonic mouse fibroblasts (NIH/3T3) after
235 seeding cells for 6 hours over PGA discs .

236 **3.3. Particle stabilization in physiological buffer:**

237 Particles incubated with PBS showed a high level of aggregation, (Figure 1). Although different
238 concentrations of polysorbate surfactants were used as potential stabilisers, they were not
239 accompanied by any improvement of particle stability (data not shown). However, 24h
240 incubation with human plasma stabilized particles successfully in PBS, resulting in particle
241 sizes ranging from 237 to 300 nm in diameter (Figure 1). A small peak of higher particle size
242 in DLS (data not shown) was noted indicating some aggregate formation (representing 14% of
243 low particle size peak by intensity).

244 The stability of NP in biological systems is an important consideration, as particles in solutions
245 with physiological salt concentrations and pH values can form micrometer-sized coarse
246 agglomerates (Deguchi et al., 2007); (Murdock et al., 2008). Coarse agglomerates of NP will
247 behave differently in a biological system compared to well-dispersed NP, especially with
248 respect to endocytic uptake of particles (Buford et al., 2007). The effectiveness of human
249 plasma in preventing aggregation could be explained by adsorption of protein molecules onto
250 the NP surface forming a protein corona (Lynch and Dawson, 2008) that is able to prevent
251 particle aggregation (Gebauer et al., 2012). The improvement of NP stabilization after 24h
252 incubation with human plasma might be due to a better and more efficient coating of NP by

253 plasma protein that was not achieved by a short incubation. This suggested a relatively slow
254 adsorption or slow equilibration process of plasma protein adsorption onto the surface of NP
255 (Casals et al., 2010). This is consistent with the study of Bihari et al, who demonstrated that
256 human, bovine and mouse serum albumins offered a better stability than Tween 80 for different
257 types of NP, TiO₂ (rutile), ZnO, Ag (silver), and carbon nanotubes in PBS. In addition, mouse
258 serum achieved a similar stabilizing effect to that achieved by pure mouse serum albumin
259 (Bihari et al., 2008). Therefore, incubation of particles with plasma for 24h was the method
260 used to stabilize the particles for subsequent studies.

261 **3.4. Investigation of virus core protein expression after Huh7.5 cells transfection with** 262 **J6/JFH1 HCV chimera:**

263 Fluorescence Microscopy was used to assess active replication in Huh7.5 cells transfected with
264 HCV genomes. Expression of virus core protein was detected 48h after transfection of Huh7.5
265 cells with J6/JFH1 and staining of the core protein using the primary antibody, C7-50 and
266 secondary antibody- Alexa488 (Figure 2). The green fluorescence observed in Figure 2B
267 represents expression of HCV core protein. Different cells were observed to have varying
268 levels of Core expression (Figure 2B). A flow cytometry study (Figure 3) was also performed
269 to assess virus transfection of Huh7.5 cells. Figure (3A) is the flow cytometry histogram, where
270 X-axis represents Alexa-488 fluorescence intensity and it is indicative of labelled virus core
271 protein and therefore it reflects the efficiency of virus transfection while Y-axis represents the
272 number of events (number of cells).

273 The red, black and blue histograms are blank1 (electroporated non-transfected Huh7.5 cells),
274 blank2 (electroporated non-transfected Huh7.5 cells, treated with primary and secondary
275 antibodies, to investigate if there a possibility of non-specific binding) and experimental
276 (electroporated transfected Huh7.5 cells, treated with primary and secondary antibodies)
277 respectively. As seen from the histogram, the red peak (Blank 1) represents the background

278 fluorescence of cells. It was found that there is a limited non-specific binding of antibodies as
279 revealed by slight shift of red peak to a black peak (Blank 2) of higher fluorescence intensity
280 along the Alexa-488 axis. Blue peak (Experimental sample to demonstrate virus replication)
281 has the highest fluorescence signal of Alexa-488 and this is indicative of virus transfection
282 success. However, not all cells in the blue peak replicated virus equally and this could be
283 demonstrated by division of blue peak into 3 sub-peaks: two small sub-peaks and a larger sub-
284 peak. A small sub-peak with a very low fluorescence signal ranging from 1 to 10 represents a
285 cell population that did not replicate virus. The second small sub-peak and the larger sub-peak
286 represent cell populations that replicated virus but with unequal efficiency, where the small
287 sub-peak with signal fluorescence ranging from 150 to 10,000 along Alexa-488 axis represents
288 the cell population with the highest efficiency of virus replication while the larger peak had a
289 lower fluorescence intensity with signal intensity ranging from 10 to 150.

290

291 Moving to flow cytometry graphs Figure 3 (B), (C), (D) representing Blank1, Blank2, and
292 Experimental respectively. X-axis represent the Alexa-488 fluorescence intensity which is
293 indicative of labelled virus core protein while Y-axis represent RBITC fluorescence intensity
294 that is indicative of NP uptake. Each graph is subdivided into 4 quadrants where the lower left
295 (LL) quadrant represents cells with a low fluorescence signal for both RBITC and labelled
296 virus core protein. Moving from LL quadrant to the lower right (LR) quadrant indicates an
297 increase of Alexa-488 fluorescence intensity that is indicative of virus transfection. As shown
298 in Figure 3 (B), for blank1, almost all cells in the population occupied the LL quadrant with a
299 very limited number of cells (0.26%) appearing in the LR quadrant. Figure 3 (C) represents
300 blank2 cells where cells occupied the same quadrants as blank1 but more cells occupied LR
301 (0.58) and this is indicative of slightly more cells with higher fluorescence intensity for Alexa-
302 488. This might reflect a non-specific binding due to treatment with primary and secondary

303 antibodies. Figure 3 (D), represents Experimental (transfected cells) where cells occupy both
304 LL and LR quadrants but LR quadrant has a higher population of cells (13.9%) than both blank
305 1 and blank 2. This demonstrated that virus transfection of Huh7.5 cells was successful due to
306 higher number of cells with higher fluorescence intensity along Alexa-488 axis. However, as
307 previously described in the flow cytometry histogram Figure 3 (A) that most cells are
308 transfected with (J6/JFH1) but not all cells equally replicated the virus. The latter means that
309 cells located in LL quadrant in graph (D) might contain some cells that are infected by Huh7.5
310 cells but do not replicate efficiently enough to be detected in LR quadrant. Although, not all
311 cells replicate virus equally, the transfected cells could be used to investigate the effect of virus
312 transfection on the uptake of RBITC PGA NP.

313 **3.5. Confocal microscopy investigation of NP uptake by virus transfected Huh7.5 cells** 314 **versus non-transfected cells:**

315 The time course of NP uptake into transfected cells was initially investigated by confocal
316 microscopy (Figure 4). A, B, C and D images represent blue, green, red fluorescence channels
317 and overlay of all channels respectively of a single plane image of transfected cells incubated
318 with NP. The red fluorescence shows RBITC PGA NP. After 0.5 h incubation, red fluorescence
319 was seen as fine dots distributed across the cells. With increasing incubation time, the number
320 of fine dots first increased, and then larger bright patches of red fluorescence were seen after
321 2h. By 4 h, there was a high level of both fine dots and patches. Some red fluorescence patches
322 of aggregated particles that were not associated with cells could also be seen (green arrows).

323 A closer examination of the fluorescence distribution in the cells at different depth through the
324 cells (different Z-stacks) by confocal microscopy is presented (Figure 5). The presence of red
325 fluorescence in the plane of the section through the nucleus demonstrated an intracellular
326 localisation of the particles. The appearance of these dots close to the peri-nuclear region
327 together with an increase of the fluorescence intensity over incubation time suggested that

328 uptake of NP by cells was a continuous endocytic process where endosomes fused together to
329 form late endosomes that are further fused to form lysosomes. It is generally accepted that most
330 nano-particulates are taken up into cells by a variety of endocytic routes (Garnett and Kallinteri,
331 2006). The physicochemical properties of NP and culture medium have a role on the interaction
332 of NP with cells. PGA polymer has COOH group that should be in the anion form at the pH
333 (7.4) of the culture medium and therefore RBITC PGA NP should carry negative charge as
334 revealed by its zeta potential value measured at pH 7.4 (HEPES buffer, 10mM), ($- 53.7 \pm$
335 13.34). upon addition of RBITC PGA NP into the culture medium, protein -corona will be
336 formed due to adsorption of different types of proteins and this should facilitate their uptake
337 into cells. This is consistent with the literature where carboxylated polystyrene particles (1 μ m
338 and 50nm) were taken up by alveolar type I cells (Fröhlich, 2012) . Park and his colleagues
339 (Park et al., 2011) prepared gold NP functionalized with aromatic thiol derivatives to produce
340 nanoparticles with a surface functional groups; NH₂, COOH and OH. Functionalized gold NP
341 were able to adsorb proteins and had been taken up into A549 cells, adenocarcinomic human
342 alveolar basal epithelial cells. It has been shown that there is not much difference of cell uptake
343 due to different surface groups due to thick protein corona formed (Park et al., 2011).
344 Therefore, it is the adsorbed layer of protein which affects NP uptake into cells rather than the
345 charge of the naked particles. The uptake of RBITC PGA NP into Huh7.5 cells is also in
346 agreement with a previous publication reporting that RBITC PGA NP are endocytosed and
347 sorted into the lysosomal compartment of DAOY cells, a human medulloblastoma cell line
348 (Meng et al., 2006).

349 A single plane confocal microscopy image of NP taken up by virus-transfected cells compared
350 to non-transfected cells after incubation for 4 h is presented (Figure 6). Non-transfected cells
351 (Figure 6A) showed a relatively small number of fine dots of red fluorescence (orange arrow)
352 that were associated with the cells compared to the significantly coarser and brighter dots seen

353 in the virus transfected cells (Figure 6B). The red fluorescence observed outside cells suggested
354 some extracellular particle aggregation had occurred (green arrows).

355 **3.6. Flow Cytometry quantitative study of NP uptake by virus transfected and non-**
356 **transfected Huh7.5 cells:**

357 Flow cytometry of NP uptake into virus transfected and non-transfected Huh7.5 cells over
358 different incubation times (0 to 4 h) was performed (Figure 7). The X-axis represents Alexa-
359 488 fluorescence intensity (indicative of virus transfection) while the Y-axis represents RBITC
360 fluorescence intensity (indicative of NP uptake). The control graph shows that the majority of
361 cells have a small shift along the X-axis demonstrating virus transfection. However, there are
362 smaller populations with no increase or a little increase of fluorescence due to labelled core
363 proteins of the virus as previously described in section 3.4. With increasing incubation time
364 there was a progressive increase in fluorescence on the Y-axis representing NP uptake for the
365 majority of the cell population in both transfected and non-transfected cells. For cells
366 electroporated with HCV there was a significant population of cells with either no significant
367 virus transfection or a low virus transfection in which no increase in NP fluorescence was
368 observed. This might be due to an effect of virus RNA on cell vitality and this requires further
369 investigation to determine whether these cells die or resume endocytosis at a later time. For
370 non-transfected cells, there is very small population of cells showing low NP uptake.

371 For better understanding of these results, it should be noted that the FACS had been set up to
372 avoid the fluorescence spill over from RBITC channel into Alexa-488 channel and vice versa.
373 The FACS had been set up using Huh7.5 cells of different properties in the following order;
374 (1) Huh7.5 cells; non-transfected cells that were not treated with NP and they were used to
375 blank the FACS. (2) a set of Huh7.5 cells; non-transfected and treated with NP to adjust red
376 channel, (3) a set of Huh7.5 cells; transfected and not treated with NP to adjust green channel
377 and (4) a set Huh7.5 cells; transfected and treated with NP to avoid spill over of fluorescence.

378 The data of fluorescence of Alexa-488 versus fluorescence of RBITC is presented (Figure 7)
379 to show that the increased fluorescence from nanoparticle uptake, is related to the fluorescence
380 from virus transfection. The relative proportion of cells (percentage of gated cells in each
381 quadrant) involved in both virus transfection and nanoparticle uptake is also presented (Table
382 2). The fluorescence from virus transfection is confined to the right half of the graph (Figure
383 7) and (LR and UR in Table 2), and the fluorescence from particle uptake is found in the upper
384 half of the graph (Figure 7) and (UL and UR in table 2). Looking at percentages of cells in
385 different quadrants (Table 2), we can see that most of the non-transfected cells did show uptake
386 of nanoparticles (UL quadrant). In contrast, in the transfected cells there was a much lower
387 percentage of cells in the UL quadrant, but also significant number of cells which show virus
388 transfection and NP uptake (UR quadrant), and non-transfected and no NP uptake (LL
389 quadrant). These changes in the numbers of cells in these quadrants show that virus
390 transfection did influence NP uptake. It should also be noted, as explained earlier (Figure 3)
391 that some of Huh7.5 cells replicate virus to a lower efficiency and might occupy the LL
392 quadrant. From the above, we could speculate that the statistics of cells (% Gated cells)
393 presented in Table 2 may underestimate the population of transfected cells in the LR quadrant
394 and may overestimate the true percentage of cells in the LL quadrant because of this population
395 of cells with a lower efficiency of transfection showing a low fluorescence of virus expression.
396 Therefore, the NP uptake detected in UL quadrant for transfected cells might involve NP uptake
397 not only due to non-transfected cells but also, virus transfected cells that replicate virus with a
398 lower efficiency.

399 Quantitative flow cytometry of NP uptake by virally transfected/non-transfected Huh7.5 cells
400 is presented (Figure 8). NP uptake by virus transfected cells was significantly higher ($P < 0.05$)
401 than non-transfected cells over all incubation time intervals, around 2 times more. It is also
402 interesting to note that the rates of uptake changed with time and the change in rates of uptake

Table 2: % Gated cells for virus transfected and non-transfected Huh7.5 cells

Time	%Gated for virus transfected Cells				%Gated for virus non-transfected cells			
	LL	UL	LR	UR	LL	UL	LR	UR
Experimental	99.34	0.03	0.58	0.05	-	-	-	-
0	31.38	51.64	4.30	12.67	27.14	72.53	0.11	0.22
0.5	13.74	66.77	1.65	17.84	2.46	97.17	0.09	0.29
1	14.15	67.82	1.60	16.42	1.47	98.11	0.09	0.32
2	13.03	67.32	1.43	18.22	1.46	97.91	0.13	0.51
3	11.10	69.18	0.82	18.90	1.09	98.46	0.07	0.38
4	10.78	68.60	0.91	19.70	1.04	98.50	0.07	0.39

Experimental: Cells electroporated in presence of HCV RNA and treated with 1ry and 2ry antibodies

LL: Lower Left quadrant; low virus transfection, low NP uptake

UL: Upper Left quadrant; low virus transfection, raised NP uptake

LR: Lower Right quadrant; raised virus transfection, low NP uptake

UR: Upper Right quadrant; raised virus transfection, raised NP uptake

403

404 differed between transfected and non-transfected cells. In non-transfected cells the rate of
 405 uptake was constant for about 2h before the rate started to drop off. However, in virus
 406 transfected cells there was a reduction in rate of uptake after a very rapid initial rate for the first
 407 hour of incubation. After this initial period the rate of uptake showed a value similar to the
 408 initial rate of uptake in non-transfected cells and this rate is then maintained for the remainder
 409 of the 4h period.

410

411 There was a slow rate of release of free RBITC from NP, and a control sample representing the
 412 amount of free dye associated with NP was also assessed. Free dye uptake was negligible after
 413 incubation with either virus transfected or non-transfected cells for 4 h and this demonstrated
 414 that fluorescence measured was due to actual NP uptake. The latter is in agreement with a

415 previous publication that reported incubation of free dye (RBITC) with DAOY cells was
416 associated with a very limited uptake compared to RBITC PGA NP (Meng et al., 2006). The
417 staining for virus core protein required membrane permeabilization by saponin, which could
418 potentially result in some leakage of NP. To account for this, control samples where cells were
419 incubated with NP but not permeabilised was assessed. There was no statistically significant
420 difference in uptake between permeabilised and non-permeabilised cells (Figure 8). The
421 enhancement of NP uptake due to virus transfection might be explained by enhancement of
422 one or more of the endocytic pathways that are responsible for NP uptake. This is consistent
423 with the previous finding that adenovirus infection enhanced macro-pinocytosis process due to
424 modulation of the cell cytoskeleton (Meier et al., 2002). The selective advantage of NP uptake
425 into virus transfected hepatocytes as presented in the current study offers a significant benefit
426 that might be attained by encapsulating antiviral agents for hepatic virus infection e.g. Hepatitis
427 B and Hepatitis C. This concept could be further extended to other viruses, but further
428 investigations is essential.

429

430 **4. Conclusions:**

431 Drug delivery using nanoparticles has been of interest since the early 1980s, but more recently
432 there have been significant advances in drug delivery using biodegradable nanoparticles. Much
433 of this interest in nanoparticle delivery systems has its focus on cancer treatment because of
434 the enhanced permeability and retention effect which provides a mechanism for selective
435 delivery or increased targeting to tumour tissue. We have additionally reported that under
436 certain conditions PGA particles also showed an enhanced uptake into DAOY
437 medulloblastoma cells in cells culture. There are other tissues where possibilities exist for
438 targeting of nanoparticles and which may be exploited therapeutically. One such possibility is
439 delivery to the liver. With this in mind we hypothesised that nanoparticle delivery may be a

440 good way to enhance delivery of antiviral agents to the liver while reducing the off-target
441 accumulation and therefore side effects of antiviral agents in case of virus liver infections e.g.
442 hepatitis B and C viruses.

443 The current work demonstrated that Huh7.5 cells, a hepatic cell line transfected with HCV
444 RNA showed a higher NP uptake than non-transfected cells. Virus transfection also resulted in
445 changes in rates of uptake with time in comparison to non-transfected cells. These data suggest
446 that polymer nanoparticles may provide a useful future delivery system for targeting virus
447 infections of liver providing that antiviral agents could be sufficiently loaded into polymer
448 nanoparticles. This approach could prove particularly effective in eradication of hepatitis B
449 virus, where elimination of the HBV covalently closed circular DNA requires selective
450 targeting of molecular therapies to latently infected hepatocytes. The application of NP directed
451 therapies for other important viral diseases is an exciting possibility that requires further
452 exploration.

453 **5- Declaration of Interest**

454 The authors declare no conflicts of interest

455 **Acknowledgment:** Yasmin Abo-zeid was funded by a studentship from the Egyptian Culture
456 Centre and Educational Bureau. Huh7.5 cells and the J6/JFH1 chimeric virus was a gift from
457 Apath L.L.C.

458

459 **References**

- 460 Bihari, P., Vippola, M., Schultes, S., Praetner, M., Khandoga, A.G., Reichel, C.A., Coester, C.,
461 Tuomi, T., Rehberg, M., Krombach, F., 2008. Optimized dispersion of nanoparticles for
462 biological in vitro and in vivo studies. Part. Fibre Toxicol. 5, 1–14.
463 <https://doi.org/10.1186/1743-8977-5-14>
- 464 Buford, M.C., Jr, R.F.H., Holian, A., 2007. A comparison of dispersing media for various
465 engineered carbon 9, 1–9. <https://doi.org/10.1186/1743-8977-4-6>
- 466 Casals, E., Pfaller, T., Duschl, A., Oostingh, G.J., Puentes, V., 2010. Time Evolution of the
467 Nanoparticle Protein Corona 4, 3623–3632.
- 468 Clercq, E. De, 2016. Approved Antiviral Drugs over the Past 50 Years 29, 695–747.

469 <https://doi.org/10.1128/CMR.00102-15.Address>

470 Deguchi, S., Yamazaki, T., Mukai, S., Usami, R., Horikoshi, K., 2007. Stabilization of C 60
471 Nanoparticles by Protein Adsorption and Its Implications for Toxicity Studies 60, 854–
472 858.

473 Fröhlich, E., 2012. The role of surface charge in cellular uptake and cytotoxicity of medical
474 nanoparticles 5577–5591.

475 Garnett, M.C., Baldwin, R.W., 1986. Endocytosis of a monoclonal antibody recognising a cell
476 surface glycoprotein antigen visualised using fluorescent conjugates 221, 214–221.

477 Garnett, M.C., Kallinteri, P., 2006. Nanomedicines and nanotoxicology: Some physiological
478 principles. *Occup. Med. (Chic. Ill)*. 56, 307–311. <https://doi.org/10.1093/occmed/kql052>

479 Gebauer, J.S., Malissek, M., Simon, S., Knauer, S.K., Maskos, M., Stauber, R.H., Peukert, W.,
480 Treuel, L., 2012. Impact of the Nanoparticle – Protein Corona on Colloidal Stability and
481 Protein Structure.

482 Hutchison, J.G.M.C., Manns, M., Patel, K., Poynard, T., Lindsay, K.L., Trepo, C., Dienstag,
483 J., Lee, W.M., Mak, C., Garaud, J.J., Albrecht, J.K., The, F.O.R., Hepatitis, I., 2002.
484 Adherence to Combination Therapy Enhances Sustained Response in Genotype-1–
485 Infected Patients With Chronic Hepatitis C 1061–1069.
486 <https://doi.org/10.1053/gast.2002.35950>

487 Kallinteri, P., Higgins, S., Hutcheon, G.A., Pourc, C.B.S., Garnett, M.C., 2005. Novel
488 Functionalized Biodegradable Polymers for Nanoparticle Drug Delivery Systems 1885–
489 1894.

490 King, A.M.Q., Adams, M.J., Carstens, E.B., Lefkowitz, E.J., 2012. Virus Taxonomy: Ninth
491 Report of the International Committee on Taxonomy of Viruses.

492 Lanford, R.E., Guerra, B., Lee, H., Averett, D.R., Pfeiffer, B., Chavez, D., Notvall, L., Bigger,
493 C., 2003. Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon ,
494 Gamma Interferon , Poly (I) -Poly (C), Tumor Necrosis Factor Alpha , and Ribavirin in
495 Hepatitis C Virus Subgenomic Replicons 77, 1092–1104.
496 <https://doi.org/10.1128/JVI.77.2.1092>

497 Lazear, H.M., Diamond, M.S., 2016. Zika Virus: New Clinical Syndromes and Its Emergence
498 in the Western Hemisphere. *J. Virol.* 90, 4864–4875. [https://doi.org/10.1128/JVI.00252-](https://doi.org/10.1128/JVI.00252-16)
499 16

500 Lembo, D., Donalisio, M., Civra, A., Argenziano, M., Lembo, D., Donalisio, M., Civra, A.,
501 Argenziano, M., 2018. Expert Opinion on Drug Delivery Nanomedicine formulations for
502 the delivery of antiviral drugs : a promising solution for the treatment of viral infections.
503 *Expert Opin. Drug Deliv.* 15, 93–114. <https://doi.org/10.1080/17425247.2017.1360863>

504 Lindenbach, B.D., Evans, M.J., Syder, A.J., Tellinghuisen, T.L., Liu, C.C., Mckeating, J.A.,
505 Rice, C.M., 2005. Complete Replication of Hepatitis C Virus in Cell Culture 623–627.

506 Lynch, I., Dawson, K.A., 2008. The key role of protein-nanoparticle interactions in
507 nanomedicine and 3, 40–47.

508 Meier, O., Boucke, K., Hammer, S.V., Keller, S., Stidwill, R.P., Hemmi, S., Greber, U.F., 2002.
509 Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-
510 mediated uptake 158, 1119–1131. <https://doi.org/10.1083/jcb.200112067>

511 Meng, W., Parker, T.L., Kallinteri, P., Walker, D.A., Higgins, S., Hutcheon, G.A., Garnett,
512 M.C., 2006. Uptake and metabolism of novel biodegradable poly (glycerol-adipate)
513 nanoparticles in DAOY monolayer 116, 314–321.
514 <https://doi.org/10.1016/j.jconrel.2006.09.014>

515 Montessori, V., Press, N., Harris, M., Akagi, L., Montaner, J.S.G., 2004. Adverse effects of

516 antiretroviral therapy for HIV infection 170, 229–238.

517 Murdock, R.C., Braydich-stolle, L., Schrand, A.M., Schlager, J.J., Hussain, S.M., Al, M.E.T.,
518 2008. Characterization of Nanomaterial Dispersion in Solution Prior to In Vitro Exposure
519 Using Dynamic Light Scattering Technique 101, 239–253.
520 <https://doi.org/10.1093/toxsci/kfm240>

521 Navarro, L., Ceaglio, N., Rintoul, I., 2017. Structure and properties of biocompatible poly (
522 glycerol adipate) elastomers modi fi ed with ethylene glycol. Nat. Publ. Gr. 1–8.
523 <https://doi.org/10.1038/pj.2017.30>

524 Nowacek, A.S., Balkundi, S., Mcmillan, J., Roy, U., Martinez-, A., Mosley, R.L., Kanmogne,
525 G., Kabanov, A. V, Gendelman, H.E., 2012. NIH Public Access 150, 204–211.
526 <https://doi.org/10.1016/j.jconrel.2010.11.019>.Analyses

527 Paixão, E.S., Barreto, F., Da Glória Teixeira, M., Da Conceição N Costa, M., Rodrigues, L.C.,
528 2016. History, epidemiology, and clinical manifestations of Zika: A systematic review.
529 Am. J. Public Health 106, 606–612. <https://doi.org/10.2105/AJPH.2016.303112>

530 Park, J., Park, J., Park, J., Park, J., Ock, K., Ganbold, E., Woong, N., Cho, K., 2011. Preferential
531 adsorption of fetal bovine serum on bare and aromatic thiol- functionalized gold surfaces
532 in cell culture media Journal of Colloid and Interface Science Preferential adsorption of
533 fetal bovine serum on bare and aromatic thiol-functionalized g. J. Colloid Interface Sci.
534 363, 105–113. <https://doi.org/10.1016/j.jcis.2011.07.006>

535 Rothan, H.A., Bahrani, H., Abdulrahman, A.Y., Mohamed, Z., Teoh, T.C., Othman, S., Rashid,
536 N.N., Rahman, N.A., Yusof, R., 2016. Mefenamic acid in combination with ribavirin
537 shows significant effects in reducing chikungunya virus infection in vitro and in vivo.
538 Antiviral Res. <https://doi.org/10.1016/j.antiviral.2016.01.006>

539 Sumpter, R.J., Loo, Y.-M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S.M., Michael
540 Gale, J., 2005. Regulating Intracellular Antiviral Defense and Permissiveness to Hepatitis
541 C Virus RNA Replication through a Cellular RNA Helicase, RIG-I 79, 2689–2699.
542 <https://doi.org/10.1128/JVI.79.5.2689>

543 Suttle, C.A., 2005. Viruses in the sea 437. <https://doi.org/10.1038/nature04160>

544 Tan, M.J.A., Gaunt, M.W., Hibberd, M.L., Nicholas Furnham, 2017. The complex relationship
545 between the emerging flaviviruses : dengue and Zika 18–21.

546 Taresco, V., Creasey, R.G., Kennon, J., Mantovani, G., Alexander, C., Burley, J.C., Garnett,
547 M.C., 2016. Variation in structure and properties of poly (glycerol adipate) via control
548 of chain branching during enzymatic. Polymer (Guildf). 89, 41–49.
549 <https://doi.org/10.1016/j.polymer.2016.02.036>

550 Taylor, L.H., Latham, S.M., Woolhouse, M.E.J., 2001. Risk factors for human disease
551 emergence. <https://doi.org/10.1098/rstb.2001.0888>

552 Wiwanitkit, S., Wiwanitkit, V., 2015. Journal of Tropical Diseases Some New Emerging Viral
553 Diseases in South America and East Africa : The 3, 2–3. <https://doi.org/10.4172/2329-891X.1000160>

555 Yeo, K.L., Chen, Y., Xu, H.Y., Dong, H., Wang, Q., Yokokawa, F., Shi, P., 2015. Synergistic
556 Suppression of Dengue Virus Replication Using a Combination of Nucleoside Analogs
557 and Nucleoside Synthesis 59, 2086–2093. <https://doi.org/10.1128/AAC.04779-14>

558 Zhang, T., Howell, B.A., Dumitrascu, A., Martin, S.J., Smith, P.B., 2014. Synthesis and
559 characterization of glycerol-adipic acid hyperbranched polyesters. Polymer (Guildf). 55,
560 5065–5072. <https://doi.org/10.1016/j.polymer.2014.08.036>

561
562

563

564

565

566





Figure 1: Effect of human plasma proteins on stability of RBITC PGA NP; The stability of NP in PBS was determined over 24h by particle size measurement using Malvern Zetasizer Nano ZS. NP showed a massive aggregation in PBS. However, incubation of particles with human plasma for 24h improved particle stability in PBS. Error bars represent SD.

567

568



A **B**

Figure 2: Fluorescence microscopy images of non-transfected/transfected Huh7.5 cells; Cells electroporated in absence of HCV RNA (J6/JFH1) (A) and in presence of J6/JFH1(B). Blue fluorescence represents nuclei stained with DAPI and the green fluorescence represents presence of HCV core protein. Images showed that virus has replicated and produced viral core protein.

569

570




Figure 3: Huh7.5 cells electroperated in absence and presence of HCV RNA (J6/JFH1); (A) the flow cytometry histogram of Blank1 (cells electroperated in absence of HCV RNA), Blank2 (cells electroperated in absence of HCV RNA and treated with 1ry and 2ry antibodies), and Experimental (cells electroperated in presence of HCV RNA and treated with 1ry and 2ry antibodies). (B), (C), and (D) are flow cytometry graphs of Blank1, Blank2 and Experimental respectively. (A) Histogram showed that most cells are transfected by (J6/JFH1) but not all cells equally replicated the virus. The latter means that cells located in LL quadrant in graph (D) contains some cells that are transfected by Huh7.5 cells but do not replicate efficiently enough to be produce a high fluorescent signal to be detected in LR quadrant.

571

572




Figure 4: Time course of Nanoparticle uptake into HCV transfected Huh7.5 cells; Confocal microscopy images of J6/JFH1 transfected Huh7.5 cells after incubation with RBITC PGA NP for different time intervals (0.5 to 4h) at 37C and 5% CO₂. A, B, C, and D images are blue, green, red channels and overlay of all channels respectively. Blue fluorescence represents nuclei stained with DAPI, green fluorescence indicates labelled virus core protein and the red fluorescence represents RBITC PGA NP. Initially, cell associated NP appeared as fine red dots finely dispersed across the cell which became coarser and associated with the peri-nuclear region as time progressed (orange arrow). Some extracellular aggregated particles were present (green arrows). Scale bar is 10 μm.

573

574




Figure 5: Intracellular localisation of Nanoparticles in J6/JFH1 Transfected Huh7.5 cells; Confocal microscopy images at different Z-planes (depth across cells) of transfected Huh7.5 cells after incubation for 2 h with RBITC PGA NP at 37C and 5% CO₂. Blue fluorescence represents nuclei stained with DAPI. Green fluorescence represents labelled virus core protein and red fluorescence represents NP. The figures show the height in the Z-stack. The red fluorescence coincident with the blue fluorescence of the nuclei is indicative that NP are inside cells.

575

576




Figure 6: Comparison of nanoparticle uptake into J6/JFH1 transfected versus non-transfected cells; Confocal microscopy images of non-transfected (A) and transfected (B) Huh-7.5 cells incubated for 4 h with RBITC PGA NP at 37°C and 5% CO₂; Blue fluorescence represents nuclei stained with DAPI; red fluorescence represents RBITC PGA NP taken up by cells (yellow arrows). Red fluorescence in transfected cells was brighter than in non-transfected cells. This indicates that virus infection enhanced NP uptake. Green arrows represent aggregated particles outside the cells, scale bar is 10 μm.

577

578




Figure 7: Flow cytometry analysis of Nanoparticle uptake into Huh7.5 cells; Flow cytometry graphs of Huh7.5 cells incubated with RBITC PGA NP for different time intervals where X-axis represents Alexa-488 fluorescence intensity; Y-axis represents RBITC fluorescence. Left column, J6/JFH1 non-transfected cells, right column, J6/JFH1 transfected cells. Blank cells (the top graph of left column) represent electroporated non-transfected cells that were not incubated with NP while control cells (the top graph of right column) represent electroporated transfected cells that were not incubated with NP. Cells show NP uptake as indicated by movement of signals from lower quadrants to upper quadrants where non-transfected cells show in the left-hand quadrants and transfected cells in the right-hand quadrants. In the transfected cells there is a small population of cells that did not take up NP.

579

580




Figure 8: Quantitation of Nanoparticle uptake into non-transfected versus transfected Huh7.5 human hepatoma cells by flow cytometry; Mean Fluorescence Intensity (MFI) was recorded for transfected and non-transfected cells incubated with fluorescently labelled polymer NP at 37° C and 5%CO₂ for different time intervals (0 upto 4 h): Rate of NP uptake by transfected cells was much higher than non-transfected cells. MFI is due to NP uptake rather than free dye uptake that might associate NP as indicated by very low MFI recovered from free dye incubated with cells for 4 h. Permeabilization process to label virus core protein was not associated with leakage of NP as indicated by similar MFI at 4h for transfected cells (cells exposed to permeabilization process) and transfected (-ve permeabilization). Error bars represent SD.